Objective： To evaluate the effect of anti-vascular endothelial growth factor （VEGF） on juxtafoveal choroidal neovascularization （CNV） secondary to multifocal choroiditis （MFC） and wet age-related macular degene...Objective： To evaluate the effect of anti-vascular endothelial growth factor （VEGF） on juxtafoveal choroidal neovascularization （CNV） secondary to multifocal choroiditis （MFC） and wet age-related macular degeneration （AMD）. Methods： In this retrospective, comparative study, 20 unique eyes with CNV were divided into two groups： 10 patients affected by MFC and 10 patients diagnosed with wet AMD. They all received local intravitreal （Ivr） injections of ranibizumab, with 6 months of follow-up. Retreatment injections were performed based on findings suggestive of active neovascularization. Results： Significant improvements were observed in the juxtafoveal CNV lesions, and average central macular thickness decreased in both groups following the anti-VEGF therapy （P〈0.05）. The average number of injections used in MFC patients was 1.6, while three injections on average were used in wet AMD patients （Z=-2.844, P=0.009）. Best-corrected visual acuity was significantly improved in MFC patients after anti-VEGF therapy （P〈0.05）, and there was no significant difference in wet AMD patients between before anti-VEGF therapy and 6 months later （P〉0.05）. Conclusions： IVT ranibizumab resulted in good clinical outcomes for juxtafoveal CNV secondary to MFC and wet AMD, but the average number of injections used in MFC was fewer than that used in wet AMD over a 6-month observation period. Compared with the wet AMD group, visual acuity was obviously improved in the MFC group at 6 months.展开更多
基金Project supported by the National Natural Science Foundation of China(No.81500760)
文摘Objective： To evaluate the effect of anti-vascular endothelial growth factor （VEGF） on juxtafoveal choroidal neovascularization （CNV） secondary to multifocal choroiditis （MFC） and wet age-related macular degeneration （AMD）. Methods： In this retrospective, comparative study, 20 unique eyes with CNV were divided into two groups： 10 patients affected by MFC and 10 patients diagnosed with wet AMD. They all received local intravitreal （Ivr） injections of ranibizumab, with 6 months of follow-up. Retreatment injections were performed based on findings suggestive of active neovascularization. Results： Significant improvements were observed in the juxtafoveal CNV lesions, and average central macular thickness decreased in both groups following the anti-VEGF therapy （P〈0.05）. The average number of injections used in MFC patients was 1.6, while three injections on average were used in wet AMD patients （Z=-2.844, P=0.009）. Best-corrected visual acuity was significantly improved in MFC patients after anti-VEGF therapy （P〈0.05）, and there was no significant difference in wet AMD patients between before anti-VEGF therapy and 6 months later （P〉0.05）. Conclusions： IVT ranibizumab resulted in good clinical outcomes for juxtafoveal CNV secondary to MFC and wet AMD, but the average number of injections used in MFC was fewer than that used in wet AMD over a 6-month observation period. Compared with the wet AMD group, visual acuity was obviously improved in the MFC group at 6 months.
文摘目的:观察银杏叶提取物对激光诱导的大鼠脉络膜新生血管(choroidal neovascularization,CNV)的疗效。方法:选取60只大鼠,随机分为4组,分别为正常组、模型组、实验组、生理盐水组,每组15只大鼠。除正常组外其余各组均行氪激光光凝制作CNV模型,模型组不做任何处理,实验组均在光凝后每日行腹腔注射银杏叶提取物(Extract of Ginkgo Biloba,EGb761),生理盐水组在光凝后每日腹腔注射生理盐水。于光凝后7,14,21d后对各组大鼠行眼底造影检查,观察CNV的渗漏情况,然后立即处死各组动物,行脉络膜视网膜切片,HE染色后观察各组视网膜及脉络膜的结构和CNV的情况。结果:荧光造影结果显示正常大鼠脉络膜无渗漏,7d时各组大鼠脉络膜渗漏均较轻微,14,21d时模型组和生理盐水组大鼠脉络膜渗漏明显,实验组大鼠脉络膜荧光素渗漏点数明显要少于对应的模型组和生理盐水组差异具有统计学意义(P<0.05)。实验组大鼠的视网膜、脉络膜结构保存比模型组更好。结论:腹腔注射EGb761可以明显减少大鼠CNV的形成,用药时间越长,疗效越好。
